RLMD RELMADA THERAPEUTICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, RELMADA THERAPEUTICS INC reported revenue of n/a, net income of −$12.9M and diluted EPS of −$0.11; for the fiscal year ended December 2025 revenue was n/a.
RLMD annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$59.1M, net income $0 (margin n/a), EPS −$1.45
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$83.9M, net income $0 (margin n/a), EPS −$2.65
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$104M, net income $0 (margin n/a), EPS −$3.28
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$161M, net income −$157M (margin n/a), EPS −$5.30
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$126M, net income −$126M (margin n/a), EPS −$7.16
RLMD quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$12.9M, EPS −$0.11
- Quarter ended Mar 31, 2026: revenue n/a, net income −$19.1M, EPS −$0.22
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income $37.5M, EPS −$0.27
- Quarter ended Sep 30, 2025: revenue n/a, net income −$10.1M, EPS −$0.30
- Quarter ended Jun 30, 2025: revenue n/a, net income −$9.87M, EPS −$0.30
- Quarter ended Mar 31, 2025: revenue n/a, net income −$17.6M, EPS −$0.58
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income $61.3M, EPS −$0.62
- Quarter ended Sep 30, 2024: revenue n/a, net income −$21.7M, EPS −$0.72
- Quarter ended Jun 30, 2024: revenue n/a, net income −$17.8M, EPS −$0.59
- Quarter ended Mar 31, 2024: revenue n/a, net income −$21.8M, EPS −$0.72
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income $73.6M, EPS −$0.84
- Quarter ended Sep 30, 2023: revenue n/a, net income −$22.0M, EPS −$0.73
- Quarter ended Jun 30, 2023: revenue n/a, net income −$25.3M, EPS −$0.84
- Quarter ended Mar 31, 2023: revenue n/a, net income −$26.3M, EPS −$0.87
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$37.9M, EPS n/a
- Quarter ended Sep 30, 2022: revenue n/a, net income −$39.4M, EPS −$1.31
- Quarter ended Jun 30, 2022: revenue n/a, net income −$39.9M, EPS −$1.33
- Quarter ended Mar 31, 2022: revenue n/a, net income −$39.7M, EPS n/a
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$34.4M, EPS −$1.82
- Quarter ended Sep 30, 2021: revenue n/a, net income −$42.6M, EPS −$2.44
RLMD cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$45.8M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$51.8M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$51.7M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$104M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$91.9M, share buybacks n/a
RLMD balance sheet
- Jun 30, 2026: cash $11.3M, total assets $219M, total liabilities $12.5M, shareholders' equity $207M
- Mar 31, 2026: cash $9.78M, total assets $235M, total liabilities $16.6M, shareholders' equity $219M
- Dec 31, 2025: cash $3.50M, total assets $94.0M, total liabilities $7.49M, shareholders' equity $86.5M
- Sep 30, 2025: cash $1.38M, total assets $14.9M, total liabilities $5.41M, shareholders' equity $9.47M
- Jun 30, 2025: cash $1.35M, total assets $21.1M, total liabilities $5.17M, shareholders' equity $15.9M
- Mar 31, 2025: cash $1.15M, total assets $27.7M, total liabilities $5.24M, shareholders' equity $22.4M
- Dec 31, 2024: cash $3.86M, total assets $45.8M, total liabilities $10.3M, shareholders' equity $35.5M
- Sep 30, 2024: cash $1.48M, total assets $55.7M, total liabilities $8.10M, shareholders' equity $47.6M
Is RLMD profitable?
No. RELMADA THERAPEUTICS INC lost $4.54M over the last four quarters.
What is RLMD's EPS?
Diluted earnings per share over the last four quarters were −$0.90; −$0.11 in the latest quarter.